Genkyotex’s GKT831 Shown to Delay Tumor Growth in Multiple Preclinical Models by Targeting Cancer Associated fibroblasts
Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that data in multiple preclinical models showed that GKT831, the Company’s NOX ...